LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (Amex:BPA) announced today that it will present new study results from the Bio-E-Gel® (transdermal estradiol gel) development program at the annual meeting of the North American Menopause Society (NAMS) in Nashville October 11-14, 2006. Bio-E-Gel is an innovative low-dose topical estrogen therapy intended to treat moderate-to-severe hot flashes in menopausal women. Bio-E-Gel has been shown to be effective at a daily dose that is 50 percent lower than the lowest dose of estradiol currently available for the treatment of hot flashes. The current study investigated if Bio-E-Gel could be “transferred” to a partner after skin contact.
